Lilly Announces Plans to Open First Gateway Labs in San Diego

n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n

Scheduled to open in the first part of 2024, Lilly’s new Gateway Labs facility, in partnership with Alexandria Real Estate Equities, will feature a world-class lab to assist marketers and clinical startups.

INDIANAPOLIS, Nov. 28, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced plans to open its first Lilly Gateway Labs location in San Diego, California, in the early part of 2024. Gateway Labs is Lilly’s shared innovation accelerator that provides committed corporations with a lab area and exclusive access to Lilly scientists, researchers, and executives, as well as exposure to Lilly’s functional and clinical expertise. This will be the company’s third Gateway Labs location, with more locations located in San Francisco and Boston.

“We are excited to expand our presence in San Diego because it is home to a thriving life sciences community,” said Daniel Skovronsky, M. D. , Ph. D. , chief scientific officer and president of Lilly Research Laboratories. “By offering laboratory area and access to Lilly’s clinical expertise, we are able to help scientists at think tanks, universities and small biotech corporations in their efforts to detect the next generation of medicines for patients. “

Companies located in Gateway Labs have the opportunity to collaborate with Lilly and others on studies of mutual interest, participate in clinical and learning-sharing symposia with Lilly experts and partners, and have the ability to make monetary investments directly from Lilly, venture capital funds, or both. In partnership with Alexandria Real Estate Equities Inc. (ARE), the new site will merge Lilly’s clinical expertise with ARE’s operational excellence to create a world-class facility.

The new site will be on the University City Center (UTC) campus in Alexandria and will offer approximately 62,000 square feet of cost-effective, flexibly designed lab space, as well as open workstations to foster clinical exchange and collaboration among committed corporations. They are expected to space out 10 corporations and more than 120 biotech and Lilly workers.

“Lilly has supported external innovation in its early stages for decades, and we are excited to continue expanding our shared innovation spaces from Gateway Labs to a broader network of life sciences startups,” said Julie Gilmore, Ph. ArrayD. , vice president and global director. . head of Gateway Labs. ” The expansion of our Gateway Labs style will provide scientists with Lilly research operations, mentorship and expertise in an environment designed to foster clinical breakthroughs.

Companies interested in joining Lilly Gateway Labs make a stopover in www. gatewaylabs. lilly. com and contact GatewayLabs@lilly. com.

About LillyLilly combines care and discovery to create medicines that improve the lives of others around the world. We have pioneered life-changing discoveries for approximately 150 years and today our medicines help more than 51 million people around the world. Harnessing the strength of biotechnology, chemistry and genetic medicine, our scientists are urgently driving new discoveries to solve some of the world’s leading mental health problems, redefining diabetes care, treating diabetic obesity and reducing its devastating long-term peak effects, advancing the fight against Alzheimer’s disease. disease, providing answers to some of the most debilitating immune disorders and transforming the most difficult-to-treat cancers into manageable diseases. With each step towards a fitter world, we are motivated by one thing: to improve the lives of millions more people. This means conducting cutting-edge clinical trials that reflect the diversity of our world and ensuring that our medicines are available and affordable. For more information, visit Lilly. com and Lilly. com/news or follow us on Facebook, Instagram, and LinkedIn. C-LLY

Refer to:

Stéfanie Prodouz; stefanie. prodouz@lilly. com; 1-317-287-9899 (Media)

Joe Fletcher; jfletcher@lilly. com; 1-317-296-2884 (Investors)

 

 

View content to download multimedia: https://www. prnewswire. com/news-releases/lilly-announces-plans-to-open-its-first-ever-gateway-labs-site-in-san-diego-301998388Arrayhtml

SOURCE Eli Lilly

Leave a Comment

Your email address will not be published. Required fields are marked *